BMI1 and head and neck squamous cell carcinoma: We observed that in all three Cisplatin-resistant HNSCC cell line sets, as well as each corresponding resistant variant, Tocilizumab suppressed Bmi-1 expression, even in the presence of Cisplatin treatment (Fig. 5C).